GSK said the US Food and Drug Administration has approved its Penmenvy drug to treat meningitis for use in individuals aged10 - 25 years.
GSK
17 February 2025 07:18:17
Source: Sharecast
The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W, and Y) which commonly cause invasive meningococcal disease (IMD).
Penmenvy combines the antigenic components of GSK's two meningococcal vaccines, Bexsero and Menveo. The regulatory application was supported by positive results from two phase III trials, which evaluated its safety, tolerability, and immune response in more than 4,800 participants, GSK said on Monday.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.